Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034065 (
pulmonary embolism
)
14,979
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Teijin and Chemo-Sero are codeveloping
CTC
-111 as a treatment for disseminated intravascular coagulation (DIC) due to protein C deficiency. The drug was launched for the treatment of protein C deficiency in Japan on January 31, 2001 and as of October 2001 was awaiting approval for the treatment of DIC, also in Japan [426762].
CTC
-111 was evaluated in a multicenter pharmacokinetic trial in venous thrombosis patients with inherited protein C deficiency.
CTC
-111 was effective in six of ten patients with venous thrombosis, six of seven patients with deep vein thrombosis and two of three patients with
pulmonary embolism
. Treatment was safe and effective and there were no serious adverse events [350149].
...
PMID:CTC-11 (Teijin). 1595 88